11 results
8-K
EX-99.1
TYRA
Tyra Biosciences Inc
5 May 22
Tyra Biosciences Reports First Quarter 2022 Financial Results and Highlights
12:00am
Receptors (FGFR), which are altered in approximately 7% of all cancers. TYRA-300 is an
FGFR3 selective inhibitor for oncology. TYRA-200 targets FGFR2 driven
10-K
2021 FY
EX-10.15
TYRA
Tyra Biosciences Inc
3 Mar 22
Annual report
4:31pm
targets;
(30) Landlord’s general overhead expenses not related to the Building;
(31) costs for janitorial services for any rentable area
10-K
2021 FY
TYRA
Tyra Biosciences Inc
3 Mar 22
Annual report
4:31pm
of drug targets, our SNÅP platform can be extended to multiple gene families and therapeutic areas. We plan to leverage our SNÅP platform to expand our … product candidates for indications outside of oncology. Specifically, we believe we can apply our SNÅP platform to targets, such as FGFR3, that have data
424B4
TYRA
Tyra Biosciences Inc
15 Sep 21
Prospectus supplement with pricing info
4:10pm
been on a specific set of drug targets, our SNÅP platform can be extended to multiple gene families and therapeutic areas. We plan to leverage our SNÅP … of designing and developing product candidates for indications outside of oncology. Specifically, we believe we can apply our SNÅP platform to targets
S-1/A
5xiv2o 5feir54qsanq
9 Sep 21
IPO registration (amended)
6:08am
S-1
qyd3o r9w
20 Aug 21
IPO registration
4:07pm
S-1
EX-10.19
u1cbozo0w0
20 Aug 21
IPO registration
4:07pm
DRS/A
8e09u3p fjpiz
2 Jul 21
Draft registration statement (amended)
12:00am
DRS
hcnb5 li4t
28 May 21
Draft registration statement
12:00am
- Prev
- 1
- Next